BiomX (NYSE American: PHGE) announced on March 9, 2026 the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer to support the company’s next growth phase. Both executives bring senior experience in M&A, corporate strategy, finance, and capital markets.

BiomX is a clinical-stage company developing natural and engineered phage therapies targeting harmful bacteria in chronic diseases; the new leaders will focus on execution, capital strategy, and investor engagement.